(selexipag)
This information is intended for US patients and caregivers to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended to promote the use of our products, nor to provide medical advice.
UPTRAVI® (selexipag)
Patient Medical Information
What is the Recommended Dosing for UPTRAVI Intravenous Injection for Pulmonary Arterial Hypertension?
Last Updated: 08/14/2024
important information about uptravi
- Before you take UPTRAVI, tell your healthcare provider if you have narrowing of the pulmonary veins, a condition called pulmonary veno-occlusive disease.1
summary
UPTRAVI given by intravenous injection
- Your healthcare provider may decide to administer UPTRAVI by intravenous (IV) injection if you are temporarily unable to take oral therapy.1
- Your healthcare provider will give you UPTRAVI into your vein through an IV line.1
- You may be administered UPTRAVI for injection twice daily as an 80-minute IV infusion.
- Your healthcare provider will decide how much UPTRAVI for injection you will receive each day, based on your current dose of UPTRAVI tablets.1
This information is provided ONLY in response to your request and is not intended as medical advice, to promote the use of our product, or suggest using it in any manner other than as described in the PRESCRIBING INFORMATION. All decisions regarding your medical treatment should be made with your healthcare professional(s). Please contact your healthcare professional(s) to discuss the information in this response.
Please refer to the attached full PRESCRIBING INFORMATION and the PATIENT MEDICATION GUIDE for UPTRAVI.1
References
| 1 | UPTRAVI (selexipag) [Prescribing Information]. Titusville, NJ: Actelion Pharmaceuticals US, Inc, a Janssen Pharmaceutical Company. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/UPTRAVI-pi.pdf |